Healome Therapeutics Secures £2M to Advance Eye Drop Technology
BIRMINGHAM, United Kingdom, July 7, 2026 Healome Therapeutics, a University of Birmingham spinout developing an innovative eye-drop matrix technology...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
BIRMINGHAM, United Kingdom, July 7, 2026 Healome Therapeutics, a University of Birmingham spinout developing an innovative eye-drop matrix technology...
NEW YORK, July 7, 2026 Regal Healthcare Capital Partners has successfully completed the final close of Fund IV, securing...
NEW YORK, April 8, 2026 Avista Healthcare Partners has announced the acquisition of Bentec Medical from Greyrock Capital Group...
MILAN, Italy, March 26, 2026 Recordati S.p.A. has confirmed receiving a non-binding indication of interest from CVC Capital Partners...
Prague, Czech Republic; London, UK; Chicago, US – September 11, 2025 – Zentiva, a leading European generics pharmaceutical company,...
